 AUSTIN, TX ACCESSWIRE August 3, 2021 Apollo Endosurgery, Inc. Apollo Nasdaq:APEN, a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2021. Highlights Achieved total revenue of 16.6 million, an increase of 194 compared to the second quarter of 2020, and a new revenue record for the Company Increased Endoscopic Suturing System ESS revenue 23 and Intragastric Balloon IGB revenue 16 on a sequential basis compared to the first quarter of 2021 Realized gross margin of 55 on favorable product mix Continued rollout of X-TackTM with now more than 120 active sites, demonstrating excellent product performance, a short learning curve, and utility in a diverse range of upper and lower GI applications Reported that the Multi-Center ESG Randomized Interventional Trial MERIT study investigators announced successful achievement of the studys primary efficacy and safety endpoints Strengthened the Apollo leadership team with the additions of Kirk Ellis as Vice President of Sales, Steve Bosrock as Vice President of Marketing Medical Education, and Jeffrey Black as Chief Financial Officer 2021 Outlook Based on results in the first half of 2021, the Company is increasing its guidance for the full year 2021 and now expects revenue between 61-63 million, compared to its prior guidance of 55-57 million. 